Lisa M. Broad

Eli Lilly (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

30h-index3.2kcitations58works6.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(27), Neuroscience and Neuropharmacology Research(25), Ion channel regulation and function(18), Nicotinic Acetylcholine Receptors Study(16), Ion Channels and Receptors(13)

Publications58 total

Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine
Cephalalgia·2025· 5 citedOpen Access
Preclinical and clinical evaluation of a novel TRPA1 antagonist LY3526318
Pain·2025· 5 citedOpen Access
Clinical proof-of-concept results with a novel TRPA1 antagonist (LY3526318) in 3 chronic pain states
Pain·2024· 10 citedOpen Access
The atypical ‘hippocampal’ glutamate receptor coupled to phospholipase D that controls stretch‐sensitivity in primary mechanosensory nerve endings is homomeric purely metabotropic GluK2
Experimental Physiology·2023· 15 citedOpen Access
TRPA1 Antagonist LY3526318 Inhibits the Cinnamaldehyde‐Evoked Dermal Blood Flow Increase: Translational Proof of Pharmacology
Clinical Pharmacology & Therapeutics·2023· 14 citedOpen Access
From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease
Cell·2021· 87 citedOpen Access
Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs
Nature Chemical Biology·2020· 46 citedOpen Access
From Structure to Clinic: Discovery of A M1 Muscarinic Acetylcholine Receptor Agonist for the Treatment of Memory Loss in Alzheimer's Disease
SSRN Electronic Journal·2020· 1 citedOpen Access
Identification and pharmacological profile of SPP1, a potent, functionally selective and brain penetrant agonist at muscarinic M <sub>1</sub> receptors
British Journal of Pharmacology·2018· 13 citedOpen Access
Bitopic Binding Mode of an M1 Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes
Molecular Pharmacology·2018· 29 citedOpen Access
In Vitro Pharmacological Characterization and In Vivo Validation of LSN3172176 a Novel M1 Selective Muscarinic Receptor Agonist Tracer Molecule for Positron Emission Tomography
Journal of Pharmacology and Experimental Therapeutics·2018· 11 citedOpen Access
Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases
Neuropharmacology·2018· 87 cited
Synthesis and Pharmacological Characterization of C4<sub>β</sub>-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1<i>S,</i>2<i>S,</i>4<i>S,</i>5<i>R,</i>6<i>S</i>)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu<sub>3</sub>Receptor Agonist
Journal of Medicinal Chemistry·2018· 26 citedOpen Access
[O1–07–05]: REGULATED RELEASE OF HYPER‐PHOSPHORYLATED, AGGREGATED AND SEEDING COMPETENT TAU FROM RODENT BRAINS AND HUMAN SYNAPTOSOMES
Alzheimer s & Dementia·2017
[P3–081]: ESTABLISHING MICROFLUIDIC DEVICES AS AN <i>IN VITRO</i> NEURONAL MODEL FOR STUDYING MOLECULAR AND FUNCTIONAL ASPECTS OF TRANSNEURONAL TAU PROPAGATION
Alzheimer s & Dementia·2017Open Access
Acetylcholine modulates gamma frequency oscillations in the hippocampus by activation of muscarinic M1 receptors
European Journal of Neuroscience·2017· 39 citedOpen Access
M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss
Journal of Clinical Investigation·2016· 78 citedOpen Access
TRPV3 in Drug Development
Pharmaceuticals·2016· 60 citedOpen Access
An Antibody Biosensor Establishes the Activation of the M1 Muscarinic Acetylcholine Receptor during Learning and Memory
Journal of Biological Chemistry·2016· 36 citedOpen Access
In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu 2/3 receptor antagonist
Neuropharmacology·2015· 22 cited
page 1 of 3Next →

Frequent Co-authors

Adrian J. Mogg(16), Helen Sanger(12), Emanuele Sher(12), Ruud Zwart(11), Christian C. Felder(9), Beverly A. Heinz(7), James W. Putney(6), Ellen M. Colvin(6), Colin W. Taylor(5), Sophie J. Bradley(5), Andrew B. Tobin(5), Kathy H. Pearson(5), Gordon I. McPhie(5), Stephen Baker(5), Gary S. Bird(4), Colin Molloy(4), Keith G. Phillips(4), Patrick M. Sexton(4), Arthur Christopoulos(4), Paul Goldsmith(4)